not disease-related
Conditions
Interventions
placebo:4g bid for one week, oral ingestion of multiple doses of placebo, a single dose of fexofenadine120mg is given to volunteers and blood samples at different time are collected
Astragalus root extract granules:4g bid for one week, oral ingestion of multiple doses of Astragalus root extract, on the 8th day a single dose of fexofenadine120mg is given to volunteers and blood sa
Sponsors
No. 88, Jiefang Road, Hangzhou, Zhejiang, China
Eligibility
Sex/Gender
Male
Age
20 Years to 25 Years
Inclusion criteria
Inclusion criteria: 1. male healthy subjects; 2. aged 18 to 40y; 3. Body weight (more than 50kg), BMI(19-25kg/m2); 4. without significant medical history and history of drug allergy; 5. non-drug abuser; 6. non-smokers and alcohol abuse; 7. All volunteers were not allowed to take any medications 2 wk before the study period; 8. volunteers can communicate well with investigator and obey the rules of the study; 9. All volunteers gave their written informed consent.
Exclusion criteria
Exclusion criteria: 1. subjects who paticipated in other clinical trials within the past 2 month; 2. subjects who donated blood within the past 1 mo or will donate blood during or after the study; 3. subjects who do not pass the general physical examinations and BP, HR or breath status are not well; 4. subjects who have significant clinical symptoms by physical examination; 5. subjects who have some health problems by electrocardiogram and laboratory tests (including complete blood count, blood biochemistry testing and urinalysis) before starting this study; 6. Invesigator thinks that the subjects are not suitable for participating the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentrations of fexofendin; | — |
Countries
China
Contacts
Public ContactQuan Zhou
Outcome results
None listed